Study of GS1191-0445 injection for hemophilia A
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial tests a new injection called GS1191-0445 for people with hemophilia A. It aims to see if it is safe and works well to prevent or treat bleeding episodes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are male and between 18 and 65 years old.
- You have been diagnosed with hemophilia A before the study.
- You have used factor VIII products at least 150 times in the past.
- You have never had a factor VIII inhibitor (your body has not made antibodies against the treatment).
- You agree to use reliable birth control (like condoms) during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial tests a new gene therapy called NGGT003 for men with severe hemophilia A. It aims to see if the treatment is safe and can help reduce bleeding episodes.
This trial tests a one-time gene therapy treatment (GS001) to help people with hemophilia A make more of the clotting factor they lack. If it works and is safe for you, it could improve how well blood clots form over time.
This trial tests a gene therapy to help your body produce more of the clotting protein (factor VIII) it's missing. It may reduce or stop the need for regular factor infusions.
This Phase 1/2 study tests a one-time gene therapy (ASC618) to help the body make clotting factor for people with hemophilia A. It may reduce bleeding and the need for factor infusions, but you must meet several safety and eligibility checks.
This Phase 1 study tests a gene therapy designed to help the body make factor VIII (FVIII), which is missing in hemophilia A. It may help reduce bleeding and the need for FVIII infusions, but it is an early-safety trial.
This early-stage trial tests a new injectable medicine called SR604 designed to help people with hemophilia A, hemophilia B, or congenital Factor VII deficiency—conditions where the blood doesn't clot properly. The study will look at how safe the medicine is and whether it reduces bleeding episodes.
Hear when a new Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.